Stayble Therapeutics recently reached an important milestone in the development of a new treatment for patients suffering from chronic back pain. The last patient has completed all visits in the company's phase IIb study in degenerative disc disease. Now the most exciting part awaits - to see if the results can confirm the treatment's intended pain relief effect. BioStock contacted CEO Andreas Gerward to find out more about the milestone of having completed all patient follow-ups.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/stayble-reports-last-patient-last-visit-in-the-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-reports-last-patient-last-visit-in-the-phase-iib-study,c3834969

(c) 2023 Cision. All rights reserved., source Press Releases - English